Current concepts in the follow-up of patients with differentiated thyroid cancer

Israel Medical Association Journal

Volumn 9, Issue 7, 2007, Pages 540-545

  Benbassat, Carlos A ^a,c   Mechlis Frish, Sara ^b,c   Guttmann, Hadassah ^d   Glaser, Benjamin ^e   Krausz, Yodphat ^e  

^a RABIN MEDICAL CENTER   (Israel)

^b MEIR MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d MACCABI HEALTHCARE SERVICES   (Israel)

^e HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Follow up; Radioactive iodine therapy; Thyroglobulin; Thyroid cancer; Thyroxine; Ultrasound

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; LITHIUM CARBONATE; MESSENGER RNA; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PENTETATE INDIUM IN 111; RECOMBINANT THYROTROPIN; TETROFOSMIN TC 99M; THALLIUM 201; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROXINE;

CANCER CLASSIFICATION; CANCER RISK; CANCER STAGING; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFICACY; DRUG POTENTIATION; ECHOGRAPHY; FOLLOW UP; HUMAN; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENT CANCER; REVIEW; RISK ASSESSMENT; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

AUTOANTIBODIES; CARCINOMA, PAPILLARY, FOLLICULAR; CONTINUITY OF PATIENT CARE; HUMANS; NECK; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECOMBINANT PROTEINS; RISK ASSESSMENT; RNA, MESSENGER; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; WHOLE BODY IMAGING;

EID: 34547572160     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz ME, O'Sullivan B. A comparison of different staging systems predictability of patient outcome: thyroid carcinoma as an example. Cancer 1997;12: 2414-23.
2. American Joint Committee on Cancer. Cancer Staging Manual. 6th edn. New York: Springer-Verlag, 2002.
3. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787-803.
4. Cooper DS, Doherty GM, Haugen BR, et al. The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16:109-42.
5. Zophel K, Wunderlich G, Smith BE. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma? Thyroid 2003;13:861-5.
6. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, LoPresti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566-75.
7. Baloch Z, Carayon P, Conte-Devox B, et al. Guidelines committee, National Academy of Clinical Biochemistry. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:3-26.
8. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003;88:1433-41.
9. Schlumberger M, Berg G, Cohen O, et al. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 2004;150:105-12.
10. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002;87:3242-7.
11. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002;87:1499-501.
12. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000:85:175-8.
13. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002;87:1490-8.
14. Torlontano M, Crocetti U, D'Aloiso L, et al. Serum thyroglobulin and 1311 whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. The role for neck ultrasonography. Eur J Endocrinol 2003;148:18-24.
15. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic 1311 whole body scan: comparison of patients treated with high 1311 activities versus untreated patients. J Clin Endocrinol Metab 2001;86:4092-7.
16. David A, Blotta A, Bondanelli M. et al. Serum thyroglobulin concentrations and 1311 whole body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid stimulating hormone. J Nucl Med 2001;42:1470-5.
17. Baudin E, Do Cao C, Cailleux AF, Leboulleux J, Travalgi P. Schlumberger M. Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. J Clin Endocrinol Metab 2003;88:1107-11.
18. Torlontanto M, Attard M, Crocetti U, et al. Follow up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004;89:3402-7.
19. Pacini F, Molinaro E, Castagna MG, et al. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 2003;88:3668-73.
20. Frates MC, Benson CB, Charboneau JW, et al. Management of thyroid nodules detected at US: Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology 2005;237: 794-800.
21. Robbins RJ, Robbins AK. Recombinant human thyrotropin and thyroid cancer management. J Clin Endocrinol Metab 2003;88:1933-8.
22. Grigsby PW, Siegel BA, Bekker S, Clutter WE, Moley JF. Preparation of patients with thyroid cancer for 1311 scintigraphy or therapy by 1-3 weeks of thyroxine discontinuation. J Nucl Med 2004;45:567-70.
23. Liel Y. Preparation for radioactive iodine administration in differentiated thyroid cancer patients. Clin Endocrinol 2002;57:523-7.
24. Serhal DI, Nasrallah MP, Arafah BM. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2004;89:3285-9.
25. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006;91:926-32.
26. Eustatia-Rutten CF, Smit JW, Romijn JA, et al. Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. Clin Endocrinol (Oxf) 2004;61:61-74.
27. Ringel MD, Ladenson PW. Controversies in the follow-up and management of well-differentiated thyroid cancer. Endocr Relat Cancer 2004;11:97-116.
28. Koong SS, Reynolds JC, Movius EG, et al. Lithium as a potential adjuvant to 1311 therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 1999;84:912-16.
29. Liu YY, Stokkel MP, Pereira AP, et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol 2006;154 525-31.
30. Helal BO, Merlet P, Toubert ME, et al. Clinical impact of (18)FFDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 2001;42:1464-9.
31. Robbins RJ, Wan O, Grewal RK, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab 2006;91:498-505.
32. Petrich T, Borner AR, Otto D, Hofmann M, Knapp WH. Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 2002;29:641-7.
33. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R. Ladenson P. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004;89:91-5.
34. Rodrigues M, Traub-Weidinger T, Leimer M, et al. Value of 111 In-DOTA-lanreotide and 111 In-DOTA-DPhe 1-Tyr3-octreotide in differentiated thyroid cancer: results of in vitro binding studies and in vivo comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:1144-51.
35. Chiovato L, Latrofa F, Braverman LE, et al. Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. Ann Intern Med 2003;139:346-51.
36. Ringel MD, Ladenson PW, Levine MA. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab 1998;83:4435-42.
37. Karavitaki N, Lembessis P, Tzanela M, Vlassopoulou V, Thalassinos N, Koutsilieris M. Molecular staging using qualitative RT-PCR analysis detecting thyreoglobulin mRNA in the peripheral blood of patients with differentiated thyroid cancer after therapy. Anticancer Res 2005;25:3135-42.
38. Elisei R, Vivaldi A, Agate L, et al. Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its use in the follow-up of differentiated thyroid cancer patients. J Clin Endocrinol Metab 2004;89:33-9.
39. Cooper DS, Specker B, Ho M, et al. Thyroid suppression and disease progression in patients with well differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8:737-44.
40. Mazzaferi EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.